Background Ultra-micronized palmitoylethanolamide (um-PEA) represents an attractive option for chronic pain control in complex older patients at higher risk of adverse effects with traditional analgesics. Objective The aim of this study was to determine the effectiveness of um-PEA versus placebo on chronic pain intensity and function in individual geriatric patients. Design We performed randomized, blinded N-of-1 trials with two 3-week um-PEA versus placebo comparisons, separated by 2-week washout periods. Participants The study included outpatients aged C 65 -years with chronic, non-cancer, non-ischemic pain in the back, joints, or limbs. Intervention Patients were randomized to Um-PEA 600 mg or placebo twice daily.
Introduction
The reported prevalence of chronic or persistent pain among the elderly is as high as 80% [1] ; osteoarthritic back pain is the most frequent noncancer cause [2] . Chronic pain and its inadequate treatment have an important impact on patient function, autonomy, quality of life, and health care resource use [3] . Age-related changes in the somatosensory system and in drug pharmacokinetics, together with a higher chance of drug-drug and drug-disease interactions, influence the efficacy and safety of the available analgesic and pain-modulating drugs [4] [5] [6] [7] [8] [9] .
In particular, a growing body of evidence suggests that immune cells like microglia and mast cells play a substantial role in the induction, amplification, and maintenance of chronic pain, especially with aging [9] [10] [11] [12] . After an injury or in the presence of an inflammatory stimulus, immune cells, which are located in proximity to sensory nerve endings and vasculature, release mediators stimulating nociceptors. Physiological activation of microglia generally leads to resolution of neuroinflammation and restoration of tissue homeostasis. With aging, both microglia and mast cells increase their reactivity to stimuli, with a consequent more robust and long-lasting production of pro-inflammatory cytokines. These findings support the hypothesis that non-neuronal cells might be important therapeutic targets for the treatment of chronic pain, especially in older persons. Palmitoylethanolamide (PEA) is an endogenous N-acyl-ethanolamina involved in the modulation of neuroinflammation processes [13] [14] [15] . In murine models of chronic inflammation and chronic or neuropathic pain, PEA has been found to reduce the recruitment and activation of mast cells, the production of pro-inflammatory mediators, and endoneural edema, thus reducing both pain and inflammation while preserving peripheral nerve morphology [13, 14] . Several products containing micronized or ultra-micronized PEA (um-PEA) are authorized in Europe as 'Food for Special Medical Purposes' (European Commission Directive 1999/21/EC). PEA-based products might represent a safe choice for pain control or modulation in older people. In a systematic review including patient-level data from randomized and non-randomized trials, PEA was found to be effective in reducing chronic pain, independently of sex, age, and type of pain, although with a smaller effect in people over age 65 years [16] . No serious productrelated adverse events were reported [16] .
Response to many drugs used to treat pain varies across individuals [16, 17] , and this is likely true for um-PEA. This likely variability, and the necessity for purchase outof-pocket, represented the rationale to use N-of-1 trials (within-patient, randomized, multi-period, crossover, blinded studies) to help decide, case by case, whether to prescribe PEA in our geriatric patients. Clinicians have previously used N-of-1 designs to optimize the pharmacological management of chronic conditions including pain, using randomization and blinding as strategies to overcome bias (e.g., natural history of the disease, placebo effect, clinician and patient expectations) that threaten the trustworthiness of the 'treat and see' trials routinely used in practice [18] [19] [20] . In this report, we present a series of N-of-1 trials addressing PEA for chronic pain in older patients, conducted in the context of our Geriatric N-of-1 Service, an experimental project we implemented taking inspiration from previous pioneering experiences [21, 22] , but in the specific setting of geriatric medicine.
Methods
A previous publication presents the full study protocol with detailed rationale and methods [23] . This study was part of the Geriatric N-of-1 Service project, approved by the ethical committee of the Fondazione IRCCS Ca' GrandaOspedale Maggiore Policlinico, Milan, Italy. The primary objective of the study was to apply the N-of-1 trial approach to test the effectiveness of um-PEA 600 mg (Normast Ò ) twice a day for chronic pain in individual patients referred to the geriatric outpatient clinic of our University Hospital. As a secondary methodological objective, the study included a meta-analysis of the N-of-1 trials performed comparing the frequentist and the Bayesian statistical approach [24, 25] . The present report focuses on the primary objective, and follows the guidelines of the CONSORT Extension for reporting N-of-1 Trials (CENT) 2015 Statement [26] .
2.1 Design Overview, Randomization, and Blindness Figure 1 presents the trials' structure. The expected total length of each trial was 18 weeks, comprising two um-PEA and placebo treatment pairs assigned in a random order according to a pairwise randomization scheme. Patients took one tablet containing either Normast Ò 600 mg or placebo orally twice daily during the treatment periods, with no use of study drug during the washout period. Patients used other pain medication on an as needed basis. The product information sheet for Normast Ò 600 mg suggests ''1-2 tabs a day for 20-30 days'', but onset times longer than 1 week might be expected ''especially for chronic pain syndromes'' [27] ; a possible carryover effect is also possible. Thus, the uncertain pharmacological characteristics of the product, and the desirability of avoiding too-long trials, dictated two pairs of treatment periods of 3 weeks each with 2-week washout intervals.
Epitech Group SpA provided the active and placebo drugs, with no other involvement in the study. The study drugs were stored at the hospital pharmacy. For each trial, a hospital pharmacist generated the random sequence of treatments using the website http://www.randomizer.org, recorded the randomization codes, and provided the study drug at the beginning of each study period, thus allowing the patients, caregivers, treating physicians, and statistician to remain blinded to the sequence of active and placebo treatment.
When the trial was concluded, the clinical investigators and statisticians interpreted the results, and discussed results with the treating physician and, when feasible, with the patient/caregiver, at first maintaining the data blinded. Only secondarily the code was broken and the definitive decision upon whether to continue um-PEA was taken.
Participants
Outpatients 65 years of age or older with a complaint of non-cancer chronic pain in the back, joints, or limbs for at least 6 months were invited to participate in the study if the treating physician considered um-PEA as a possible treatment option for the patient but was uncertain about its advisability. We excluded patients with subacute or chronic limb ischemia and those who had recently commenced a new pharmacologic or non-pharmacologic treatment for pain.
Outcomes
In each N-of-1 trial, patients rated the intensity of their pain daily using an 11-point (from 0 to 10) visual numeric scale [28] in which labels and pictures (modified from the Faces Pain Scale [29] ) were included with the numeric horizontal line [eFigure 1, see electronic supplementary material (ESM)]. In the same daily sheet, the patient was asked to also report every time he/she needed to take analgesic medications, specifying the name and dosage. The impact of pain on daily activities was evaluated at the end of each week, using a short questionnaire modified from the Back Pain Functional Scale (BPFS) [30, 31] . The BPFS consists of 12 items investigating performance at work, hobbies, home activities, bending or stooping, putting on shoes or socks, lifting, sleeping, standing, walking, climbing stairs, sitting, and driving. We modified the BPFS by allowing patients to omit items that did not apply when the patient was not used to performing that activity, regardless of pain (e.g., if she was not used to driving or had no specific hobbies); while items that could potentially apply but were 'impossible' to the patient because of the pain were kept in. Each item was rated using a Likert five-point scale (1 = no difficulty performing the activity; 2 = little difficulty; 3 = medium difficulty; 4 = great difficulty; 5 = impossible to perform the activity). The statistical analysis was based on the mean score of the completed items.
The physicians reported their intention regarding whether or not to treat the patient with um-PEA before and after the trial, answering the question ''If the patient was not going to participate in the trial, would you treat him/her with um-PEA?'' before the trial, and the question ''Now that the trial has terminated and you know the results, would you continue treating the patient with um-PEA?'' after the trial. Both before and after, the physicians also Fig. 1 N-of-1 trial design. wo Washout answered the question ''How comfortable do you feel now about your treatment plan?'' using a seven-point scale [22] .
Statistical Methods
In accordance with the primary study objective, each trial was analyzed separately. For each patient, the effect on daily pain intensity was represented graphically as the mean scores over each week and over each period. A similar graphical presentation was used for the weekly scores of function impairment. The effect of the active treatment versus placebo in each patient was first statistically evaluated through a paired t test of the period mean scores within treatment pairs, as previously done in similar studies [22] . Secondarily, to use a more statistically powerful approach, we analyzed the patient's daily data on pain intensity, or the weekly data on function impairment, without aggregating them into period mean scores, in linear mixed effect models, with the daily data on pain intensity or the weekly data on function impairment as the dependent variable, and the treatment (active vs placebo) as the independent variable. We used mixed-effect models, at first, to include the treatment pair (first or second pair) as random intercept, in order to account for a possible correlation between data within the pair, to be consistent with the trial design, and allow comparison with the paired t test analyses. However, using the likelihood ratio test, for each trial we compared the mixed-effect model with a linear regression model to verify the pairwise structure of the data. The main analyses were performed assuming that the washout periods were sufficient to overcome the possible carryover effect of PEA. As sensitivity analyses, the models were repeated after excluding the measures made during the first week of each period in order to account for a slow onset time and/or a residual carryover effect [32] . When the graphical representation suggested a clear trend over time (e.g., pain or function ratings consistently increased or decreased over the course of the trial regardless of the treatment, with a visual difference between the first two and the last two periods of treatment), we statistically verified this by including in the model an interaction term between treatment and pair (e.g., first pair of treatment versus second pair of treatment), and discussed a possible reason with the patient.
Missing data were expected. No imputation method was planned. If more than three measures of the daily pain intensity in the same week were missing for at least 1 week, the period mean score was computed weighting each week's mean score according to the inverse-variance method [33] .
Given the heterogeneity in the way they were reported, data on the daily use of pain medications, on a demand basis, were not formally analyzed. They were summarized for each week as the weekly mean number of times in a day in which the patient took a medication (any type, any dosage), and included in the graphical representation that was shown to the patient and the treating physician as an additional element for discussion (eFigure 2, see ESM).
Each trial was eventually classified according to its completeness and the statistical significance of its results (threshold p value B 0.1).
Results
In the period between September 2015 and March 2016, we suggested participation to 11 patients referred to the outpatient geriatric clinic with chronic pain who met the eligibility criteria. The study flow diagram is reported in eFigure 3 (see ESM). Table 1 presents the baseline characteristics of the 10 patients who initially consented to participate and started the trial. All patients were female, with a mean age of 83.2 years (SD 4.6 years). Only three patients were on chronic analgesic therapy at the time of enrolment (patients 2, 5, 10), with a history of multiple pharmacological failures, and different pain etiologies additional to osteoarthritis. All patients had been taking painkillers on demand. Table 2 synthesizes the methods and completeness of individual N-of-1 trials. Three patients did not complete the trial. Patient 1 interrupted the trial because of diarrhea in the first 4 days, during which she was taking placebo. Patient 4 withdrew before the last period, but since her adherence was suspected to be low since the beginning because of behavioral issues (eventually found to be related to an initial dementia), we did not further consider her data. In one case (patient 10), the trial was interrupted due to intercurrent illness. Among the seven patients in which the trial was conducted through the last period, outcome questionnaires were returned with no missing data in one case (patient 5); in the case of patient 3, the questionnaires for periods 3 and 4 were lost and never returned; in all the other cases, questionnaires were returned with few missing data. Table 3 presents results on pain intensity of individual trials according to different statistical approaches. Figure 2 shows the corresponding graphical results as presented to the treating physicians, patients, and caregivers. eTable 1 (see ESM) presents individual results of functional impairment. eTable 2 (see ESM) presents a more detailed synthesis of outcome data of the N-of-1 trial of patient 5. Table 3 shows the impact on the physician's therapeutic choice and confidence, and follow-up data.
Overall, both daily pain intensity scores (Table 3 ; Fig. 2 ) and weekly function impairment scores (eTable 1, see ESM) generally showed small variations over the trial. None of the studies showed a statistically significant difference in pain intensity between um-PEA and placebo using the paired t test of mean period pain intensities (Table 3) . A statistically significant effect was seen at the mixed method analyses either in favor of um-PEA for patients 2 and 9 (with an effect size that corresponded in both cases to about 8% of the baseline pain), or in favor of placebo for patients 3 and 5. The sensitivity analyses accounting for a possible carryover effect and slow onset not sufficiently overcome by the scheduled washout supported a probable favorable effect of um-PEA in patients 2 and 9, and suggested a possible favorable effect in patient 5 and 6. In patient 5, the graphical representation (Fig. 2 ) The baseline pain intensity and function impairment for each patient has been defined as the mean between the value given on the day in which the patient consented to the trial and the value given on the first day of the trial, to take into account the daily fluctuations of chronic pain. Indeed, these two values were substantially different in some patients ADL basic Activity of Daily Living (Katz scale), eGFR estimated glomerular filtration rate (CockcroftGault formula), IADL Instrumental Activity of Daily Living (Lawton scale), MMSE Mini Mental State Examination, SD standard deviation suggested a slow onset, the need for drug titration, and a delayed carryover effect. A pair effect was statistically significant in patients 8 and 9. In the former case, it was mainly attributed to the onset of stomachache in the second part of the trial; in the latter, a clear reason for a sharp pain improvement in the second part of the trial could not be found. The reported daily need for on-demand pain medication was consistent with the intensity of pain. A statistically significant favorable effect on function impairment was seen only in patient 7 (eTable 2, see ESM), who on average reported a relatively low impact on functional impairment during the trial according to the questionnaire, and eventually placed a low value on the effect on function against the lack of effect on pain intensity. Periods were considered completed when the patient followed the trial design and took the active drug or placebo or nothing, according to the schedule, regardless of the presence and number of missing outcome data. See Fig. 1 for each trial structure and period numbering Table 3 Results of completed N-of-1 trials: effect on pain intensity, physician's treating plan and confidence, and follow-up data ID Pain intensity [28, 29] Physician's treating plan and confidence Not to treat (7) No (12) The patient had started pregabalin some months before with partial pain relief To treat (6) Yes (4) The patient referred a mild effect on pain after the first month of open therapy and was prescribed with continuing um-PEA every other month To treat (4) Not to treat (6) No (10) The patient never showed up at the scheduled follow-up visits at the geriatric clinic in the 8 months after the completion of the trial. She was contacted by phone To treat (4) Not to treat (6) No (9) The patient referred a spontaneous attenuation of her back pain. The stomachache she had referred during the trial occurred intermittently also later Table 3 continued ID Pain intensity [28, 29] Physician's treating plan and confidence To treat (6) Yes (5) The patient referred a satisfactory control of her pain with um-PEA and on-demand acetaminophen Pain intensity data were missing for the entire week for 2 weeks of the same period (period 5, while the patient was taking placebo). The results shown in the table were obtained computing the mean period score ignoring the missing data. Secondarily, the mean difference was also computed weighting each period mean score based on data missingness using the inverse-variance method. Even if only 7 out of 21 assessments were available, they all corresponded to a score of 7. Thus, the analysis based on the inverse-variance method (taking into account the number of assessments but also the data variance) provided a larger statistically significant effect size favoring the active drug (with high data heterogeneity according to the I-squared test)
f Data missing for every week of period 3 and every week of period 4 (washout) because outcome assessments were lost and not returned g Paired t test on period means could not be performed because data for the entire period 3 were missing. For this patient, the table shown the results for the paired t test on week means of the second pair of treatment h All weeks with missing data were in washout periods
After the discussion of the results and experience of the trial with the treating physicians, patients, and caregivers, four patients continued with um-PEA (Table 3) . In all four, the physician's intention before the trial was to treat with um-PEA; in two patients, the level of confidence in the decision increased after the trial, and in two cases it remained the same ( Table 3 ). Three of these four patients were still using um-PEA at the first clinical follow-up (Table 3) . Three patients were not prescribed um-PEA; in one case this coincided with the physician's pre-trial intention, while in two cases the physician's intention before the trial was to treat the patient. In all three cases, the confidence in the decision increased after the trial.
Discussion
We report the results of a series of N-of-1 trials to test the efficacy of um-PEA in reducing chronic non-cancer pain and its impact on function performed in older outpatients referred to the geriatric clinic of our university hospital in Milan. We found a statistically significant favorable impact on either pain intensity or function impairment in three of seven patients that completed the trial; in the other four completed trials, the results did not reach a statistical significance or were in favor of placebo. After the trial, um-PEA was prescribed to four patients. In two patients, the physician changed her pre-trial intention to treat the patient with um-PEA based on trial results. In five patients, the clinician expressed greater confidence in the decision after the trial; in two patients the pre-trial level of confidence (i.e., ''Quite comfortable, likely that the treatment plan is best for the patient'') was unaffected by the trial.
Our study has several strengths. It was the first time a series of N-of-1 trials was implemented with the aim of optimizing pain medication through an empirical, objective, and personalized approach, specifically in geriatric patients. These N-of-1 trials represent a pilot of a wider project aiming to create a Geriatric N-of-1 Service, based on the rationale that older complex patients are underrepresented in the current paradigms of evidence-based medicine [34, 35] , are extremely heterogeneous, and are often exposed to therapeutic failures and adverse events. Such patients therefore stand to benefit from use of a method that would establish or refute benefit with greater certainty than conventional multiple 'try and see' trials [19] , and from an approach that would put patient characteristics, needs, and preferences at the center [36, 37] . The specific context of chronic pain management, often associated with long-term use of multiple medications and abuse of nutraceuticals despite unclear benefit [38, 39] , and the specific case of um-PEA, with the need for the patient to pay for the product cost, contributed to our motivation. Our experience has commonalities with previous experiences with N-of-1 trials not specifically conducted in a geriatric setting [22, 23, 40] . First, the approach helped to strengthen the confidence in the therapeutic decisions, whether the decision was a confirmation of a pre-trial intention or not, and, often, independently of the statistical significance of the results. Second, the graphical representation of the results, more than statistics, played a role in the decision-making process involving patients, caregivers, and treating physicians, as it did in similar experiences [22] . The lack of power of statistical tests, and the potentially compelling impact of the visual presentation of results, has made practitioners of single-subject studies question the necessity of statistical tests [41] . The analysis of N-of-1 trials based on a paired t test is consistent with treatment periods being the unit of randomization, and with the pairwise structure, but it is known to have a limited statistical power [42] . Visual presentation of results mitigates this limitation in practice. However, we were aware that patients, caregivers, and above all, physicians, even when able to appreciate the visual presentation, would sometimes rely on us for advice on the trial results from a more analytical perspective. Thus, we decided to also use mixed methods, which, still accounting for the trial structure, would allow the use of all the daily (or weekly) outcome measurements, yielding a greater power. Therefore, the difference in the statistical significance of the results between the two tests, for the same trial, in some of the patients, was somewhat expected.
We also learned lessons regarding the feasibility of this approach with the oldest patients. Compliance and reliability of the patients represented the main anticipated threats to the trials, which we tried to reduce through enrolling patients whom we had already evaluated based on a comprehensive geriatric assessment, who appeared to be keen to undertake such a type of trial that would help them with their pain, and who, in a screening visit, when instructed on how to complete the questionnaire, demonstrated their ability to do so. In fact, in only one of 10 patients did the trial fail because of the patient's noncompliance, which corresponds to a similar noncompliance rate (10%) found in a previous report of a 3-year experience with N-of-1 trials and a case mix that also included younger patients [22] .
In terms of adherence to the drug protocol, in their proofof-concept series of N-of-1 trials on statin-related myalgia in patients with a relatively lower mean age than ours (66 years, female in 7 of 8 cases) [40] , Joy and colleagues reported a 92-100% adherence based on pill counts. We decided not to formally assess adherence in this way because it would not definitely prove a correct daily dose regimen. Similarly, previous reports of N-of-1 trials have also described instances in which patients forgot to complete the questionnaires for a certain period, or lost the questionnaires, or did not adhere temporarily to the trial design [40] . In some cases, we suspected, on the basis of clinical contact and the way the patients completed the questionnaires, that their reliability was lower than expected from their Mini Mental State Examination (MMSE) score at the screening visit. In some patients, especially in those with no etiologies other than osteoarthritis, we suspected that the patient's inurement to pain, together with reduced discernment abilities, explained average moderate outcome scores with small variation. Indeed, the fact that most of these patients, despite complaining about pain, were not on chronic analgesic therapy, was already a clue for their tendency to resist pain. In particular, it has been our own experience that older patients tend to underestimate the medical importance of pain, compared with other medical conditions they are affected by, which might be a fact related to age but also to our own cultural background, and therefore not necessarily generalizable. However, we cannot rule out that our patients were not on any chronic analgesics because of (patient's or physician's) low confidence in their efficacy and/or safety, or because pain had been previously underestimated or overlooked by other physicians. Finally, we encountered social barriers that we tried to address. For instance, in one patient, because she lived alone and had mobility limitations, we delivered the study drugs and questionnaires to her home. In another patient, because there were no close relatives, we engaged the patient's friend, who eventually withdrew from her caregiving role.
Lastly, we experienced some feasibility issues previously described as obstacles to the adoption of N-of-1 trials in practice: difficulties in educating, involving and keeping engaged the medical staff [43] . Conversely, we easily succeeded in involving the hospital pharmacy to store and deliver the study drugs, generate the randomization schemes, and ensure blindness.
Limitations
In designing the study, we needed to compromise to take into account the expected pharmacological characteristics of um-PEA. Hence, we conducted trials of about 4 months each, with the awareness that we were at the limit beyond which important criteria for an N-of-1 trial to succeed, including patient compliance and clinical stability, are jeopardized [41, 44] . Second, we designed the study based on evidence about the product pharmacokinetics and pharmacodynamics that are not definitive, with a possible inter-individual variability that could not be anticipated. Our trials could be an opportunity to explore the product characteristics further; yet, the trial structure might not have been completely appropriate to study the product efficacy in every case. Third, even though chosen after a careful review of the relevant literature, we could not rule out that the instruments we used were not fully appropriate; in particular, we could not rule out that the instruments' limitations contributed to the small variations that the patients overall reported.
Conclusions
Our series of N-of-1 trials on um-PEA to reduce the intensity and the impact on function in chronic non-cancer pain in a geriatric outpatient setting represented the opportunity to test the feasibility of this approach to make personalized evidence-based decisions in complex older patients. We can confirm that the approach remains attractive in this population, but requires special considerations beyond those suggested in the users' guide proposed by the pioneers of the method [41, 44] . Our experience demonstrates that the final objective of creating ''a real clinical learning community'' [45] was achieved, and that the approach facilitates older patients' desire to participate in decision making and research [46] .
